Immunological investigations · 2026
Toll-Like Receptor 3 Inhibition Reduces Vasoconstriction and Blood Pressure in Spontaneously Hypertensive Rats via COX-1 Downregulation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Santos Santana Taynara, Dela Justina Vanessa, Alves de Freitas Raiany, Pedrosa Nunes Kenia, Giachini Vitorino Fernanda Regina, Lima Victor Vitorino
Аннотация
BACKGROUND: Toll-like receptors (TLRs) are implicated in blood pressure (BP) regulation, but the role of TLR3 in hypertension remains poorly understood. We hypothesized that anti-TLR3 treatment reduces vasoconstriction and lowers BP in hypertension.
METHODS: To test this, spontaneously hypertensive rats (SHR) and normotensive Wistar controls were treated with either IgG or an anti-TLR3 antibody. BP was measured, and mesenteric arteries were assessed for vascular reactivity, protein expression, and histology.
RESULTS: Anti-TLR3 treatment significantly reduced BP in SHR. It also decreased the contractile response to noradrenaline, an effect abolished by indomethacin, and prevented the increased COX-1 expression in SHR while reducing COX-2 expression in both strains. Furthermore, anti-TLR3 reduced collagen I and increased collagen III deposition in the mesenteric artery and lowered TLR3 expression in the tunica media of SHR.
CONCLUSION: These findings support TLR3 may represent a novel therapeutic target in hypertension.
METHODS: To test this, spontaneously hypertensive rats (SHR) and normotensive Wistar controls were treated with either IgG or an anti-TLR3 antibody. BP was measured, and mesenteric arteries were assessed for vascular reactivity, protein expression, and histology.
RESULTS: Anti-TLR3 treatment significantly reduced BP in SHR. It also decreased the contractile response to noradrenaline, an effect abolished by indomethacin, and prevented the increased COX-1 expression in SHR while reducing COX-2 expression in both strains. Furthermore, anti-TLR3 reduced collagen I and increased collagen III deposition in the mesenteric artery and lowered TLR3 expression in the tunica media of SHR.
CONCLUSION: These findings support TLR3 may represent a novel therapeutic target in hypertension.